Although the pCR rate did not reach statistical significance, it indicates that inetetamab exhibits favorable efficacy like trastuzumab in neoadjuvant treatment of HER2-positive LABC, which warrants further exploration in subsequent studies.
← all excerpts
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
1
—
—